1. Nanotechnology therapy for Alzheimer′s disease memory impairment attenuation
- Author
-
Samo Ribarič
- Subjects
0301 basic medicine ,Aging ,memory impairment ,Review ,Disease ,Animals, Genetically Modified ,lcsh:Chemistry ,Amyloid beta-Protein Precursor ,Mice ,0302 clinical medicine ,Medicine ,Cognitive impairment ,lcsh:QH301-705.5 ,Spectroscopy ,education.field_of_study ,nanodelci ,biology ,nanotechnology ,Brain ,nano particles ,General Medicine ,Alzheimerjeva bolezen ,animal models ,Computer Science Applications ,Nanomedicine ,živalski modeli ,motnje spomina ,Alzheimer’s disease ,Tau protein ,Population ,Mice, Transgenic ,tau Proteins ,Nanotechnology ,Catalysis ,Inorganic Chemistry ,03 medical and health sciences ,Animal model ,Alzheimer Disease ,Memory ,Animals ,Humans ,Learning ,Memory impairment ,Cognitive Dysfunction ,Physical and Theoretical Chemistry ,education ,Molecular Biology ,Memory Disorders ,Recall ,business.industry ,Organic Chemistry ,Rats ,Disease Models, Animal ,030104 developmental biology ,lcsh:Biology (General) ,lcsh:QD1-999 ,Mutation ,Etiology ,biology.protein ,Dementia ,business ,030217 neurology & neurosurgery ,nanotehnologija - Abstract
Currently, there is no cure for Alzheimer’s disease (AD) in humans; treatment is symptomatic only. Aging of the population, together with an unhealthy diet and lifestyle, contribute to the steady, global increase of AD patients. This increase creates significant health, societal and economical challenges even for the most developed countries. AD progresses from an asymptomatic stage to a progressively worsening cognitive impairment. The AD cognitive impairment is underpinned by progressive memory impairment, an increasing inability to recall recent events, to execute recently planned actions, and to learn. These changes prevent the AD patient from leading an independent and fulfilling life. Nanotechnology (NT) enables a new, alternative pathway for development of AD treatment interventions. At present, the NT treatments for attenuation of AD memory impairment are at the animal model stage. Over the past four years, there has been a steady increase in publications of AD animal models with a wide variety of original NT treatment interventions, able to attenuate memory impairment. NT therapy development, in animal models of AD, is faced with the twin challenges of the nature of AD, a chronic impairment, unique to human, of the tau protein and A β peptides that regulate several key physiological brain processes, and the incomplete understanding of AD′s aetiology. This paper reviews the state-of-the-art in NT based treatments for AD memory impairment in animal models and discusses the future work for translation to the successful treatment of AD cognitive impairment in human.
- Published
- 2022